Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
GAITHERSBURG, Md., Nov. 5, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2026.
"This quarter, we continued to execute across all three pillars of our strategy," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health."
Third Quarter 2026 and Recent Highlights
Key Business Highlights
Third Quarter 2026 Total Revenue
$ in millions
Q3 2026
Q3 2025
Change
%
Product Sales 1
$ 26
$ 13
$ 12
91 %
Sanofi 2
19
48
(30)
(61 %)
Takeda
7
6
1
14 %
Serum
5
2
3
136 %
Other Partners 3
11
0
11
100 %
Licensing, Royalties
and Other Revenue
43
57
(14)
(25 %)
Total Revenue
$ 68
$ 70
$ (2)
(3 %)
Notes
1.
Product Sales includes both Novavax's Nuvaxovid sales and Supply sales. Nuvaxovid Sales reflects product sales where Novavax is the commercial market lead and records revenue related to the sales and distribution of its COVID-19 vaccine. Supply Sales includes sales of finished product, adjuvant and other supplies from Novavax to its license partners.
2.
Sanofi includes revenue recognized under the license agreement including upfront payments, milestones, royalties and transition services reimbursement.
3.
Other Partners in Q3 2026 reflects non-cash deferred royalty recognition related to SK bioscience prior sales of Nuvaxovid.
Third Quarter 2026 Financial Results
Financial Framework
Improves Full Year 2026 Financial Guidance
Novavax improved its Full Year 2026 Financial Guidance at mid-point by reducing Combined R&D and SG&A Expense guidance while maintaining Non-GAAP Combined R&D and SG&A Expense guidance and expects to achieve the following results:
$ in millions
Full Year 2026
(as of Nov 5 2026)
Full Year 2026
(as of Aug 6 2026)
Combined R&D and SG&A Expenses
$375 - $395
$370 - $410
Less: R&D Reimbursements
($60)
($60 - $70)
Non-GAAP Combined R&D and SG&A
Expenses
$315 - $335
$310 - $340
Non-GAAP Combined R&D and SG&A Expenses exclude R&D Reimbursements, which are amounts reimbursed by Novavax's license partners. See "Non-GAAP Financial Measures" below. R&D Reimbursements are recorded as revenue under Licensing, Royalties and Other Revenue.
Raises Full Year 2026 Revenue Framework
For 2026, Novavax raised its 2026 Revenue Framework and expects to achieve the following results for Adjusted Total Revenue.
$ in millions
Full Year 2026
(as of Nov 5, 2026)
Full Year 2026
(as of Aug 6, 2026)
Nuvaxovid Product Sales 1
$40 - $50
$35 - $45
Adjusted Supply Sales 2
$50 - $60
$45 - $55
Sanofi CIC Milestone 3
$125
No guidance
Adjusted Licensing, Royalties and
Other Revenue 4
$170 - $180
$155 - $175
Adjusted Total Revenue 5
$385 - $415
$235 - $275
Sanofi Supply Sales, Sanofi Royalties
and future Sanofi Milestones
No guidance
No guidance
Novavax transitioned lead commercial responsibility of Nuvaxovid beginning with the 2025-2026 COVID-19 vaccination season to Sanofi for select markets. Since Novavax is reliant on Sanofi's sales forecasts for certain revenue components, these are not included in the Full Year 2026 Revenue Framework.
Revenue Framework Footnotes
Revenue Category
Revenue Framework Footnotes
Nuvaxovid Product
Sales 1
$40 million to $50 million in Nuvaxovid Product Sales by Novavax under existing Advance Purchase Agreements and commercial agreements. Expect to exclude from the 2027 Revenue Framework.
Adjusted Supply
Sales 2
$50 million to $60 million in Adjusted Supply Sales associated with collaborations with the Serum Institute on R21/Matrix-M™ and collaboration partners for COVID-19 vaccine, including Serum and Takeda and other partner related clinical and commercial supply sales.
Sanofi CIC Milestone 3
$125 million milestone earned in October 2026 with the initiation of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
Adjusted Licensing,
Royalties and Other Revenue 4
•
$60 million in R&D Reimbursement. Under the Sanofi co-exclusive licensing agreement, Novavax is eligible to receive reimbursement for costs incurred related to select R&D and technology transfer activities during the transition performance period. $5 million expected in 2027.
•
$70 million to $80 million in Other Partner related revenue including royalties and milestones from Pfizer, Serum on R21/Matrix-M and collaboration partners for COVID-19 vaccine, including Serum and Takeda. Includes a $30 million upfront payment under the Pfizer agreement received in the first quarter of 2026.
•
$40 million amortization related to the $500 million Upfront Payment and the $50 million Database Lock Milestone. Revenue recognition will occur over the transition performance period. Less than $5 million expected in 2027 to complete amortization.
Adjusted Total
Revenue 5
•
Adjusted Total Revenue is a Non-GAAP Financial Measure. Adjusted Total Revenue is total revenue excluding Sanofi Supply Sales, Sanofi Royalties and future Sanofi Milestones. See "Non-GAAP Financial Measures."
Components of Revenue excluded from the Full Year 2026 Revenue Framework are described below.
Sanofi Supply Sales
Sanofi Royalties
Sanofi Milestones
Conference Call
Novavax will discuss third quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 5, 2026. Dial-in information can be found here. A webcast of the conference call can also be accessed on the Novavax website at ir.novavax.com/events.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, targeted and capital-efficient R&D innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid, R21™/Matrix-M), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.
Non-GAAP Financial Measures
The Company presents the following non-GAAP financial measures in this press release: Non-GAAP Combined R&D and SG&A Expenses, Adjusted Total Revenue and Adjusted Licensing, Royalties and Other Revenue. Non-GAAP financial measures refer to financial information adjusted from financial measures prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company believes that the presentation of these adjusted financial measures is useful to investors as they provide additional information on comparisons between periods by including certain items that affect overall comparability. The Company uses these non-GAAP financial measures for business planning purposes and to consider underlying trends of its business. Non-GAAP financial measures should be considered in addition to, and not as an alternative for, the Company's reported results prepared in accordance with GAAP. Our use of non-GAAP financial measures may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures. The Company is unable to reconcile these revenue forward-looking non-GAAP financial measures to the most directly comparable GAAP measures without unreasonable effort because the Company is reliant on partner sales forecasts for certain revenue categories, which are not available.
Forward-Looking Statements
This press release contains forward-looking statements relating to the future of Novavax, its mission; its corporate strategy and operating plans, objectives and prospects; its value drivers and strategic priorities; its partnerships, including expectations with respect to potential partner product sales and royalties, milestones and other commercial objectives, and cost reimbursement, Matrix-M's potential utility in partners' vaccine portfolios or oncology programs and plans for additional potential partnering activities; the development of Novavax's clinical and preclinical product candidates and pipeline advancement opportunities the conduct, timing and potential results from clinical trials, conducted by Novavax or its partners, ; expectations as to the timing and outcome of future and pending regulatory filings and actions; full year 2026 financial guidance and revenue framework; and Novavax's future financial or business performance and profitability goals. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, its partner Sanofi's ability to successfully and maintain full U.S. Food and Drug Administration licensure or foreign regulatory approvals necessary to manufacture, market, distribute or deliver Nuvaxovid; our ability to obtain adequate additional funding to maintain our current level of operations and fund the further development of our vaccine candidates; challenges related to Novavax's partnership with Sanofi, including collaboration on the Nuvaxovid postmarking commitment, and in pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; its partners experiencing manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Nuvaxovid and the impact of any delays or disruptions in their operations; the impact of potential legislative, regulatory or policy changes under the current presidential administration, including any adverse impact funding for vaccine R&D, reimbursement for vaccines and their administration, vaccine mandates and recommendations and public perception of vaccine importance; uncertainty with respect to pricing, third-party reimbursement and healthcare reform; the impact of any new or changes in interpretations of existing trade measures, including tariffs, embargoes, sanctions, import restrictions and export licensing requirements; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; its partners' ability to timely deliver doses; challenges in our partner Sanofi achieving commercial adoption and market acceptance of its COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidates, stand-alone influenza vaccine candidates or other candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
NOVAVAX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share information)
Three Months Ended
Nine Months Ended
September 30,
September 30,
2026
2025
2026
2025
(unaudited)
(unaudited)
Revenue:
Product sales
$ 25,693
$ 13,442
$ 86,747
$ 645,844
Licensing, royalties and other
42,605
57,003
177,763
330,496
Total revenue
68,298
70,445
264,510
976,340
Expenses:
Cost of sales
23,488
21,496
68,429
50,936
Research and development
52,446
98,274
218,611
266,444
Selling, general and administrative
23,645
31,655
79,087
123,357
Impairment of assets held for sale
—
97,038
—
97,038
Total expenses
99,579
248,463
366,127
537,775
Income (loss) from operations
(31,281)
(178,018)
(101,617)
438,565
Other income (expense):
Interest expense
(5,401)
(5,482)
(15,991)
(16,723)
Loss on debt extinguishment
—
(28,714)
—
(28,714)
Other income, net
7,028
9,178
27,772
31,136
Income (loss) before income tax expense
(29,654)
(203,036)
(89,836)
424,264
Income tax expense (benefit)
1,722
(657)
4,418
1,489
Net income (loss)
$ (31,376)
$ (202,379)
$ (94,254)
$ 422,775
Net income (loss) per share:
Basic
$ (0.19)
$ (1.25)
$ (0.57)
$ 2.61
Diluted
$ (0.19)
$ (1.25)
$ (0.57)
$ 2.53
Weighted average number of common
shares outstanding:
Basic
164,924
162,353
164,264
161,811
Diluted
164,924
162,353
164,264
168,195
SELECTED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
September 30, 2026
December 31, 2025
(unaudited)
Cash and cash equivalents
$ 222,455
$ 240,634
Marketable securities
399,908
494,450
Total restricted cash
4,602
15,418
Total current assets
707,956
978,276
Working capital
378,111
518,326
Total assets
888,005
1,176,512
Long-term debt
292,088
244,213
Total stockholders' deficit
(216,855)
(127,753)
NOVAVAX, INC.
Reconciliation of GAAP to NON-GAAP Financial Results
(unaudited)
Three Months Ended
Nine Months Ended
($ in millions)
September 30,
September 30,
2026
2025
2026
2025
R&D Expenses
$52.4
$98.3
$218.6
$266.4
Adjustments:
R&D Reimbursement
3.8
45.8
54.1
63.6
Non-GAAP R&D Expenses
$48.7
$52.4
$164.5
$202.9
Combined R&D and SG&A Expenses
$76.1
$129.9
$297.7
$389.8
Adjustments:
R&D Reimbursement
3.8
45.8
54.1
63.6
Non-GAAP Combined R&D and SG&A
Expenses
$72.3
$84.1
$243.6
$326.2
Contacts:
Investors
Naina Zaman
240-410-5353
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com
SOURCE Novavax, Inc.